4 Not-Too-Scary Ways to Make Money on Biotech Stocks
Here's how you can invest in biotech without too much fear.
3 Reasons Why Afrezza's Launch Has Been So Disappointing
Management blames its slow start for Afrezza, the company's inhaled insulin and only approved drug, on these three factors.
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
The breakdown on which companies' numbers are easiest to swallow.
The 3 Most Disappointing Drug Launches of All Time
Treatments with huge promise don't always pan out the way you'd expect.